JNK2 Upregulates Hypoxia-Inducible Factors and Contributes to Hypoxia-Induced Erythropoiesis and Pulmonary Hypertension

Marc A. Sala¹, Cong Chen¹, Qiao Zhang¹, Hanh Chi Do-Umehara¹, Wenjiao Wu¹, Alexander V. Misharin¹, Gregory B. Waypa², Deyu Fang³, G.R. Budinger¹, Shuwen Liu⁴, Navdeep S. Chandel¹, Paul T. Schumacker², Jacob I. Sznajder¹, Jing Liu¹

¹Division of Pulmonary and Critical Care Medicine and the ²Department of Pediatrics, and the ³Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, 60611, USA. ⁴School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.

Material included:

Supplemental Figure 1
Supplemental Figure 1: Jnk1<sup>−/−</sup> or Jnk2<sup>−/−</sup> MEFs are deficient in JNK1 or JNK2 mRNA, respectively.  

**A**, Quantitative PCR for relative JNK1 mRNA expression after normalizing to HPRT in untreated WT, Jnk1<sup>−/−</sup> or Jnk2<sup>−/−</sup> MEFs.  

**B**, Quantitative PCR for relative JNK2 mRNA expression after normalizing to HPRT in untreated WT, Jnk1<sup>−/−</sup> or Jnk2<sup>−/−</sup> MEFs.  

**C**, HIF-1α immunoblots from WT, Jnk1<sup>−/−</sup> or Jnk2<sup>−/−</sup> MEFs treated with hypoxia for 0 min, 30 min, 60 min, or 2 h. Data are representative of at least 3 independent experiments that yielded similar results. All data are presented as mean +/- S.E. Statistical significance was determined by one-way ANOVA with Tukey’s post test (*, p≤0.05; **, p≤0.01; ***, p≤0.001; ****, p≤0.0001).